Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 80

1.

Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients.

Miyase S, Haraoka K, Ouchida Y, Morishita Y, Fujiyama S.

J Gastroenterol. 2012 Sep;47(9):1014-21. doi: 10.1007/s00535-012-0560-9. Epub 2012 Mar 2.

PMID:
22382633
2.

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD.

Ann Intern Med. 2012 Feb 21;156(4):271-8. doi: 10.7326/0003-4819-156-4-201202210-00004. Erratum in: Ann Intern Med. 2012 Jun 5;156(11):840.

PMID:
22351712
3.

Preliminary study of two antiviral agents for hepatitis C genotype 1.

Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C.

N Engl J Med. 2012 Jan 19;366(3):216-24. doi: 10.1056/NEJMoa1104430.

4.

Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.

Mach TH, Cieśla A, Warunek W, Janas-Skulina U, Cibor D, Owczarek D, Ciećko-Michalska I.

Pol Arch Med Wewn. 2011 Dec;121(12):434-9.

5.

Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care.

Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Delahooke TE, Dillon JF, Forrest E, Fraser A, Gillespie R, Goldberg DJ, Kennedy N, McDonald S, McLeod A, Mills PR, Morris J, Hayes P; Hepatitis C Clinical Database Monitoring Committee..

Hepatology. 2011 Nov;54(5):1547-58. doi: 10.1002/hep.24561. Erratum in: Hepatology. 2011 Dec;54(6)2280-2.

PMID:
22045672
6.

Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial.

Ghany MG, Kim HY, Stoddard A, Wright EC, Seeff LB, Lok AS; HALT-C Trial Group..

Hepatology. 2011 Nov;54(5):1527-37. doi: 10.1002/hep.24550.

7.

QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.

Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM; QUADAS-2 Group..

Ann Intern Med. 2011 Oct 18;155(8):529-36. doi: 10.7326/0003-4819-155-8-201110180-00009.

PMID:
22007046
8.

Hepatocellular carcinoma.

El-Serag HB.

N Engl J Med. 2011 Sep 22;365(12):1118-27. doi: 10.1056/NEJMra1001683. Review. No abstract available.

PMID:
21992124
9.
10.

Response-guided telaprevir combination treatment for hepatitis C virus infection.

Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F; ILLUMINATE Study Team..

N Engl J Med. 2011 Sep 15;365(11):1014-24. doi: 10.1056/NEJMoa1014463. Erratum in: N Engl J Med. 2011 Oct 20;365(16):1551.

11.

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.

Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N.

J Hepatol. 2012 Jan;56(1):78-84. doi: 10.1016/j.jhep.2011.07.016. Epub 2011 Aug 7.

PMID:
21827730
12.

Long-term cohort study of chronic hepatitis C according to interferon efficacy.

Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O.

J Gastroenterol Hepatol. 2012 Feb;27(2):291-9. doi: 10.1111/j.1440-1746.2011.06871.x.

PMID:
21793911
13.

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.

Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rücker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JP.

BMJ. 2011 Jul 22;343:d4002. doi: 10.1136/bmj.d4002. No abstract available.

PMID:
21784880
14.

Telaprevir for previously untreated chronic hepatitis C virus infection.

Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team..

N Engl J Med. 2011 Jun 23;364(25):2405-16. doi: 10.1056/NEJMoa1012912.

15.

Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials.

Singal AK, Jampana SC, Anand BS.

Dig Dis Sci. 2011 Aug;56(8):2221-6. doi: 10.1007/s10620-011-1765-0. Epub 2011 Jun 4. Review.

PMID:
21643737
16.

Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program.

Fu R, Gartlehner G, Grant M, Shamliyan T, Sedrakyan A, Wilt TJ, Griffith L, Oremus M, Raina P, Ismaila A, Santaguida P, Lau J, Trikalinos TA.

J Clin Epidemiol. 2011 Nov;64(11):1187-97. doi: 10.1016/j.jclinepi.2010.08.010. Epub 2011 Apr 7.

PMID:
21477993
17.

Boceprevir for untreated chronic HCV genotype 1 infection.

Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators..

N Engl J Med. 2011 Mar 31;364(13):1195-206. doi: 10.1056/NEJMoa1010494.

18.

Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.

Pearlman BL, Traub N.

Clin Infect Dis. 2011 Apr 1;52(7):889-900. doi: 10.1093/cid/cir076. Review.

PMID:
21427396
19.

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA.

Clin Gastroenterol Hepatol. 2011 Jun;9(6):509-516.e1. doi: 10.1016/j.cgh.2011.03.004. Epub 2011 Mar 11.

PMID:
21397729
20.

Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.

Kamal SM, Ahmed A, Mahmoud S, Nabegh L, El Gohary I, Obadan I, Hafez T, Ghoraba D, Aziz AA, Metaoei M.

Liver Int. 2011 Mar;31(3):401-11. doi: 10.1111/j.1478-3231.2010.02435.x. Epub 2011 Jan 11.

PMID:
21281434

Supplemental Content

Support Center